














HarvaDefibrotide for the Treatment of Severe Hepatic
Veno-Occlusive Disease and Multiorgan Failure
after Stem Cell Transplantation: A Multicenter,
Randomized, Dose-Finding Trial
Paul G. Richardson,1 Robert J. Soiffer,1 Joseph H. Antin,1 Hajime Uno,2 Zhezhen Jin,3
Joanne Kurtzberg,4 Paul L. Martin,4 Gideon Steinbach,5 Karen F. Murray,6
Georgia B. Vogelsang,7 Allen R. Chen,7 Amrita Krishnan,8 Nancy A. Kernan,9 David E. Avigan,1
Thomas R. Spitzer,1 Howard M. Shulman,5 Donald N. Di Salvo,10 Carolyn Revta,1
Diane Warren,1 Parisa Momtaz,1 Gary Bradwin,11 L. J. Wei,12 Massimo Iacobelli,13
George B. McDonald,5 Eva C. Guinan14Therapeutic options for severe hepatic veno-occlusive disease (VOD) are limited and outcomes are dismal,
but early phase I/II studies have suggested promising activity and acceptable toxicity using the novel polydis-
perse oligonucleotide defibrotide. This randomized phase II dose-finding trial determined the efficacy of
defibrotide in patients with severe VOD following hematopoietic stem cell transplantation (HSCT) and iden-
tified an appropriate dose for future trials. Adult and pediatric patients received either lower-dose (arm A:
25 mg/kg/day; n 5 75) or higher-dose (arm B: 40 mg/kg/day; n 5 74) i.v. defibrotide administered in divided
doses every 6 hours for $14 days or until complete response, VOD progression, or any unacceptable tox-
icity occurred. Overall complete response and day 1100 post-HSCT survival rates were 46% and 42%,
respectively, with no significant difference between treatment arms. The incidence of treatment-related
adverse events was low (8% overall; 7% in arm A, 10% in arm B); there was no significant difference in the
overall rate of adverse events between treatment arms. Early stabilization or decreased bilirubin was asso-
ciated with better response and day 1100 survival, and decreased plasminogen activator inhibitor type 1
(PAI-1) during treatment was associated with better outcome; changes were similar in both treatment
arms. Defibrotide 25 or 40 mg/kg/day also appears effective in treating severe VOD following HSCT.
In the absence of any differences in activity, toxicity or changes in PAI-1 level, defibrotide 25 mg/kg/day
was selected for ongoing phase III trials in VOD.
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The condition usually develops before day 130
post-HSCT, although it can occur later [1,2,4]; its
reported incidence varies from 5% to 60%, and it is
typically associated with the conditioning regimen used
as well as the donor source, being more common
after allogeneic HSCT than after autologous HSCT
[4-7]. The presentation of VOD ranges from mild,
reversible disease to a severe syndrome associated with
multiorgan failure (MOF) and death [4-6]. Severe
VOD is one of the most frequent causes of early death
in the HSCT setting, with a mortality rate of up to
98%–100% by day 1100 post-HSCT in adults, and
marginally lower mortality in children [5,6,8].
Hepatic VOD is also known as sinusoidal obstruc-
tion syndrome (SOS) or VOD/SOS, reflecting the
primary injury typically caused by cytoreductive agents
to sinusoidal endothelial cells in zone 3 of the hepatic
acinus [9,10]. Secondary events include sinusoidal
hemostasis leading to elevated sinusoidal pressure and
dilatation, subendothelial edema within small hepatic
venules, and deposition of fibrinogen and factor VIII
in both sinusoids and within hepatic venules [9,11].
These events are followed by ischemia, hepatocyte
necrosis, collagen deposition, and sinusoidal fibrosis,
leading to sinusoidal obstruction followed by sclerosis
and occlusion of hepatic venules [9-11]. As these pro-
cesses progress, widespread intrahepatic zonal dis-
ruption leads to portal hypertension, worsening liver
dysfunction, and ascites, eventually resulting in MOF
(characterized by pulmonary and renal dysfunction, as
well as encephalopathy) and death [10,11].
Current standard treatments for hepatic VOD
are supportive, including diuresis, transfusion, renal
replacement therapy, and analgesia. There are few
effective options that target the underlying cause.
Reduced-intensity conditioning regimens, individual-
ized chemotherapy dosing, and avoidance of cyclophos-
phamide (Cy) are currently experimental approaches
to prevention, but these strategies often are not suit-
able for chemoresistant hematologic malignancies [1].
Administration of intravenous busulfan and pharmaco-
kinetic (PK) monitoring of busulfan and Cy have been
shown to reduce the frequency of VOD [12]. Prophy-
lactic ursodeoxycholic acid use has been associated
with decreased incidence of VOD in some studies, al-
though the relative effects on cholestatic versus sinusoi-
dal injury per se are unclear [13]. Currently, there is no
proven effective therapy for either prevention or treat-
ment of hepatic VOD. Interventional studies that have
investigated prostaglandin E1, tissue-plasminogen acti-
vator (t-PA), heparin, and antithrombin III (ATIII) for
treating severe VOD have demonstrated neither signif-
icant effectiveness nor safety in this setting [14-16].
Indeed, the use of t-PA in patients with severe VOD
and MOF has been associated with markedly excessive
toxicity, precluding its use in this population [14].Defibrotide is a polydisperse oligonucleotide
with local antithrombotic, anti-ischemic, and anti-
inflammatory activity. It binds to the vascular endothe-
lium, modulates platelet activity, promotes fibrinolysis,
decreases thrombin generation and activity, and
reduces circulating levels of plasminogen activator
inhibitor type 1 (PAI-1) [17-21]. Defibrotide has
selective and protective effects on the small vessels, but
not macrovascular, endothelium [22,23]. Experimental
models suggest that it may enhance endothelial cell
survival and stabilize microvasculature [24]. Defibro-
tide has no protective effect on tumors, and in fact
was found to enhance the antitumor activity of vari-
ous agents in preclinical studies [25]. In adult and
pediatric patients with VOD, defibrotide treatment
has been associated with complete response (CR) rates
of 36%–76%, with day1100 post-HSCT survival rates
of 32%–79% and no substantial defibrotide-associated
toxicity [26-30]. Multicenter phase I/II trials of
defibrotide have included intrapatient dose escalation
from 10 mg/kg/day to 60 mg/kg/day [26-28]. In the
largest study published to date, the majority of CRs
occurred at doses of 20-40 mg/kg/day [28].
The objectives of our dose-finding trial were to (1)
determine the CR rate in patients with severe VOD
following HSCT treated with defibrotide at 25 or
40 mg/kg/day, (2) assess the safety profile of defibro-
tide at these doses in this population, and (3) determine
the dose for use in phase III and other future trials in
VOD. The trial also aimed to generate preliminary
descriptive PK data for defibrotide in a limited subset
of patients.MATERIALS AND METHODS
Patients
Adult or pediatric patients with a clinical diagnosis
of hepatic VOD, defined as the presence of jaundice
(total serum bilirubin$2 mg/dL) and at least 2 associ-
ated signs, including ascites, weight gain .5% from
baseline, hepatomegaly, or right upper quadrant
pain, by day 135 post-HSCT were considered eligi-
ble. Abdominal Doppler ultrasound was performed
at trial entry to identify the presence/absence of portal
vein blood flow reversal and confirm diagnostic find-
ings. Patients with jaundice and portal vein blood
flow reversal on Doppler examination and only one
other diagnostic criteria were eligible for the trial.
For patients with preexisting hepatomegaly, confirma-
tion of liver size increase after admission by physical
examination or imaging was required. Patients who
did not meet all criteria but had biopsy-proven VOD
were also eligible. In patients with concurrent con-
founding causes of liver dysfunction, positive biopsy
findings or a wedged transhepatic venous pressure
gradient $10 mm Hg was required to confirm
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aging studies used to clarify the diagnosis. All central
pathology reviews were performed by a single investi-
gator (H.M.S.). Recuts of all liver specimens from nee-
dle biopsies and autopsies were stained at the Seattle
Cancer Care Alliance pathology laboratory with he-
matoxylin and eosin, Mason trichrome, and Gordon-
Sweet reticulin stains. Hepatic VOD was diagnosed
based on the finding of hepatic venules with luminal
narrowing from subendothelial edema and entrapped
red cells or connective tissue. A small specimen
without adequate hepatic venules was not considered
evaluable even if it exhibited other stigmata of VOD,
such as sinusoidal fibrosis and centrilobular hemor-
rhagic necrosis.
Patient eligibility was also determined according
to the Bearman criteria and/or the presence of MOF.
Patients assessed based on the Bearman model [31]
had to have a predicted $30% risk of severe VOD.
As described previously [28], patients not assessed by
the Bearman model were eligible if they had concom-
itant MOF (presence of renal, pulmonary, and/or
central nervous system dysfunction). MOF was defined
as follows:
 Renal: creatinine$2 times the level at admission for
conditioning or $2 times the lowest level during
conditioning, or creatinine clearance or glomerular
filtration rate #50% the level at admission, or dial-
ysis dependence
 Pulmonary: oxygenation saturation#90% on room
air and/or the need for positive pressure/ventilator
dependence not attributable to any other cause
 Central nervous system: confusion, lethargy, and/or
delirium not attributable to any other cause.
Exclusion criteria included significant uncon-
trolled acute bleeding; hemodynamic instability
requiring multiple vasopressors; grade B-D graft-
versus-host disease (GVHD) according to the Interna-
tional Bone Marrow Transplant Registry Severity
Index [32], excluding grade B skin-only GVHD; intu-
bation for documented intrinsic lung disease (eg, focal
pneumonia), excluding intubation secondary to a
mechanical barrier to ventilation in the presence of
adequate oxygenation parameters (partial pressure of
oxygen [PaO2]/fraction of inspired oxygen [FiO2] ratio
$300 and/or oxygen index [OI 5 (mean arterial pres-
sureFiO2)/PaO2 100]#25%) at enrollment; grade
4 (National Cancer Institute’s CTC version 2.0) neuro-
toxicity, excluding confusion and/or delirium; previous
or concomitant systemic t-PA therapy; concomitant
use of heparin or other anticoagulants (discontinuation
of heparin treatment $12 hours before enrollment
rendered patients eligible), excluding use for routine
central venous line (CVL) management, fibrinolytic
instillation for CVL occlusion, intermittent dialysis,
or ultrafiltration; and current treatment with anotherexperimental agent. Concomitant treatment with anti-
thrombin III or other antithrombotics, nonsteroidal
anti-inflammatory drugs, or ursodiol was not permit-
ted (although ursodiol could be used in specific circum-
stances, such as radiologically confirmed bile sludging).
Study Design
This was a multicenter, randomized, dose-finding,
opened-label, phase II trial performed at 6 U.S. sites
between April 2000 and April 2006 (NCT00003966;
ClinicalTrials.gov). Patients were randomized to
lower-dose (arm A) or higher-dose (arm B) defibrotide
(Gentium, Como, Italy). Randomization was stratified
by whether or not the conditioning regimen included
Cy and by age (adult [$18 years] vs pediatric [\18
years]). For both treatment arms, the defibrotide start-
ing dose was 2.5 mg/kg every 6 hours for 4 doses (total
dose, 10 mg/kg), based on baseline weight, defined as
weight on the date of admission to the transplantation
unit for conditioning. This initial dose was intended
to ensure tolerance before dose escalation. The dose
was then increased to 6.25 mg/kg every 6 hours (total
dose, 25 mg/kg/day) in arm A and to 10 mg/kg every
6 hours (total dose 40 mg/kg/day) in arm B. Defibrotide
was administered i.v. in 5% dextrose in water, mixed to
a maximum concentration of 4 mg/mL, with the dose
rounded to the nearest 10 mg. Patients were treated
for a minimum of 14 days or until achievement of
CR, or until progression of VOD, unacceptable toxic-
ity (recurrent grade 3/4 adverse events [AEs] consid-
ered likely or definitely related to defibrotide), or
comorbidities precluded further treatment. During
therapy, wherever possible, transfusions were used to
maintain platelets $20,000/mL and hematocrit $30%
(although transfusion support was not formally moni-
tored as part of the study), with factor replacement
targeting a prothrombin time#15 seconds and fibrin-
ogen $150 mg/mL. Other appropriate supportive
care was continued as necessary, although routine use
of low-dose dopamine was discouraged because it could
increase splanchnic pooling, reducing renal plasma
flow. The study protocol was approved by an indepen-
dent institutional review board at each participating
site. All trial participants (or their parents/guardians/
health care proxy) gave written informed consent.
Assessments
The primary endpoint was CR rate. CR was de-
fined as total serum bilirubin\2 mg/dL after initiation
of defibrotide with resolution of VOD-related MOF.
Resolution of renal, pulmonary, and central nervous
system dysfunction were defined as, respectively, cre-
atinine decrease to\2 times baseline and/or resolution
of dialysis dependence, resolution of oxygen require-
ment, and resolution of encephalopathy.
Secondary endpoints included safety and tolerabil-
ity of defibrotide, effect of defibrotide on PAI-1, and
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day 1100 mortality, and/or PAI-1 level. Patients
were followed for evidence of expected AEs (includ-
ing bleeding; allergic reactions; vasomotor effects
including flushing, dizziness, headache, and hypoten-
sion; nausea; vomiting; diarrhea; and fever) and
defibrotide-attributable grade 3/4 end-organ dysfunc-
tion. Blood samples for analysis of PAI-1 and bilirubin
levels were obtained at baseline, twice weekly during
therapy, and at the end of treatment.
Additional planned objectives were to determine
the feasibility of PK analysis and to generate some pre-
liminary descriptive PK data for defibrotide in a subset
of patients. These study objectives were added by
amending the protocol after almost half of the patients
had been enrolled, and thus they were an optional part
of the protocol, limited to a small number of patients.
Blood samples for PK analysis were obtained on treat-
ment days 1, 2, and 7 (for adults: 12 samples/day, just
before the start of the first infusion; at 30, 60, 90,
and 115 minutes after the start of first infusion; and
at 5, 10, 15, 20, 30, 45, and 60 minutes after the end
of the first infusion; for pediatric patients: 2 samples/
day, just before the start of the first infusion and 115
minutes after the start of the first infusion). PK samples
were analyzed centrally using high-performance liquid
chromatography and agarose gel methods.
Abdominal Doppler ultrasound was performed at
study entry, on day 14, and after the completion of
therapy. Ultrasound images were reviewed locally
and then centrally by a single investigator (D.N.D.S).
The liver was assessed for size, with the right, left,
and caudate lobes measured separately. The gallblad-
der was evaluated for sludge and wall thickness. Ascites
were graded as absent, trace/small, or moderate/large.
Portal vein Doppler ultrasonography was performed
on the main, right, and left portal veins; pulsed Dopp-
ler tracings of each segment were graded in terms of
the presence/absence of pulsatility and flow direction.
Hepatic artery resistive indices, as well as hepatic vein
tracings, were obtained. Pathology assessments were
performed locally on available liver tissue and reviewed
centrally as detailed previously.Statistical Analyses
The planned sample size was 140 patients (70
patients/arm). It was anticipated that both arms would
exhibit defibrotide activity as assessed by CR rate. The
treatment was to be considered promising if the lower
limit of the 95% confidence interval (CI) for the CR
rate was .18%. With this design, the probability
that the treatment would be considered further was
0.82 when the true CR rate was 33%. If the number
of observed CRs were 21 of the 70 patients (ie, 30%
CR rate) in each arm, then the corresponding 95%
CI would be 18%–48% with 70 patients. If, asanticipated, both arms exhibited defibrotide activity,
then the less-toxic dose (ie, with a lower rate of severe
or worse toxicity) would be taken forward for further
investigation. In the absence of any significant
differences in activity, toxicity, or change in PAI-1
level, the lower dose would be taken forward.
All randomized patients who received one or more
doses of defibrotide (treated population) were included
in baseline, survival, and safety analyses. All random-
ized patients who received 3 or more days of defibro-
tide therapy (evaluable population) were included in
response analyses; this was to allow for administration
of 4 initial doses, after which the dose was escalated to
25 or 40 mg/kg/day. It was felt necessary to give
patients 1 day (ie, 4 doses) at the initial dose to assess
for safety, and at least 1 day (ie, 4 doses) at the treat-
ment dose before evaluating for response, to allow
meaningful comparison between arms.
For the primary efficacy analysis, 95% CIs for CR
rates by treatment arm were calculated to confirm that
the lower limits were.18%. Point estimates with 95%
CIs were reported for CR and day 1100 post-HSCT
survival rates, as well as for the differences in rates
between arms. Rates were analyzed in subgroups
defined by age (adult/pediatric) and previous therapy.
Rates were compared between arms and subgroups
using Fisher’s exact test to provide descriptive P values
as a reference. The distributions of time from HSCT
or randomization to death were estimated using the
Kaplan-Meier method; the log-rank test was applied
for comparisons of survival between arms.
PAI-1 and total bilirubin levels were summarized
at baseline, day 7, and day 14 of treatment; changes
from baseline to days 7 and 14 are reported. The asso-
ciation of radiology and pathology review findings
with response and survival was examined as well. Sum-
mary statistics are reported for PK data.RESULTS
Patient Demographics and Disposition
A total of 151 patients were randomized (Figure 1),
of whom 149 received one or more doses of defibrotide
(arm A: n5 75; arm B: n5 74) and 141 were evaluable
for response (arm A: n 5 72; arm B: n 5 69). Patient
demographic and baseline characteristics were well
balanced between the 2 arms (Table 1). The majority
of patients were caucasian (81% in arm A and 77%
in arm B). The characteristics of VOD did nor differ
between the 2 arms (Table 2).Defibrotide Administration
The majority of patients (n 5 119; 80%) received
their first defibrotide dose on the day of randomization.
The median duration of therapy was 19 days (range,
Figure 1. Disposition of patients. Flowchart illustrating the progression of patients with severe hepatic VOD after HSCT by treatment group (armA, 25
mg/kg/day i.v. defibrotide; arm B, 40 mg/kg/day i.v. defibrotide).
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arm B. Reasons for ending treatment were resolution
of VOD per protocol-defined criteria (33% in arm A
and 30% in arm B), VOD progression (15% and
19%), death (13% and 16%), patient discharge (12%
and 11%), withdrawal of care (13% and 9%), alterna-
tive diagnosis (5% and 3%), and AEs (8% and 12%,
of which 3% and 5%, respectively, were considered
defibrotide-related toxicity).
Efficacy
The overall CR rate in the evaluable population
was 46%, with 49% (95% CI, 37%–69%) in arm A
and 43% (95% CI, 32%255.2%) in arm B (Table 3).
The difference between arms (arm B - arm A) of
25% (95% CI: 222% to 11%) was not statistically
significant (P 5 .613). Overall, 42% of the patients
in the treated population were alive at day 1100
post-HSCT, 44% (95% CI, 33%255%) in arm A
and 39% (95% CI, 28%250%) in arm B (Table 3).
The difference between arms (B - A) of 25% (95%
CI, 221% to 11%) was not statistically significant
(P 5 .619). In the patients who died by day 1100
post-HSCT, the most common cause of death was
progressive VOD (29% in arm A and 28% in arm B).
Kaplan-Meier estimates for survival distribution
post-HSCT or after randomization demonstrated no
notable differences between the 2 arms (Figure 2). In
subgroup analyses by age group, the day1100 survivalrate in pediatric patients appeared to be higher in arm
A (70% vs 36% in arm B; P5 .020). Survival distribu-
tions by arm and age group showed no significant dif-
ferences between the 2 arms, although the curves
appear to be better for arm A in pediatric patients
(Figure 3C and D), consistent with day 1100 survival
rate data.
In exploratory subgroup analyses, overall CR rate
was higher in pediatric patients compared with adult
patients (57% vs 40%; P 5 .056), primarily in arm A
(70% vs 39%; P 5 .015). Overall day 1100 post-
HSCT survival rate also was higher in pediatric pa-
tients (52% vs 37%; P 5 .074), because of differences
in arm A (70% vs 33%; P5 .003). The CR rate did not
appear to be affected by sirolimus/tacrolimus therapy,
but previous exposure to gemtuzumab ozogamicin was
associated with a possible trend toward a higher CR
rate (58% vs 44%; P 5 .268). The day 1100 survival
rate was lower overall (33% vs 47%; P 5 .092) and
also in arm A (29% vs 55%; P 5 .028) for patients
who received sirolimus/tacrolimus; in contrast, previ-
ous exposure to gemtuzumab ozogamicin did not ap-
pear to be associated with reduced survival (Table 3).
CR and day1100 survival rates were compared by
patient MOF status. Assuming the overall CR (46%)
and day 1100 survival (42%) rates as fixed values,
patients who were dialysis- or ventilator-dependent
at baseline did not have statistically significantly differ-
ent CR and day 1100 survival rates, whereas those
Table 1. Demographic and Baseline Characteristics (Treated Population) of All Patients and by Treatment Arm
Characteristic Arm A (n 5 75) Arm B (n 5 74) All Patients (n 5 149)
Age group, n (%)
<18 years (pediatric) 23 (31) 25 (34) 48 (32)
$18 years (adult) 52 (69) 49 (66) 101 (68)
Median age (range), years 32 (0-61) 34 (0-63) 34 (0-63)
Sex, n (%)
Male 41 (55) 44 (59) 85 (57)
Female 34 (45) 30 (41) 64 (43)
Weight, kg, median (range) 65.9 (7-126) 65.6 (4-111) 65.8 (4-126)
Eastern Cooperative Oncology Group performance status, n (%)
#2 9 (12) 5 (7) 14 (9)
3 27 (36) 28 (38) 55 (37)
4 17 (23) 20 (27) 37 (25)
Unknown 22 (29) 21 (28) 43 (29)
Primary disease, n (%)
Acute myelogenous leukemia 18 (24) 29 (39) 47 (32)
Acute lymphoblastic leukemia 11 (15) 4 (5) 15 (10)
Chronic myelogenous leukemia 6 (8) 4 (5) 10 (7)
Other leukemia 1 (1) 0 1 (1)
Myelodysplastic syndrome 10 (13) 4 (5) 14 (9)
Non-Hodgkin lymphoma 10 (13) 9 (12) 19 (13)
Hodgkin lymphoma 3 (4) 6 (8) 9 (6)
Multiple myeloma 1 (1) 0 1 (1)
Aplastic anemia 1 (1) 1 (1) 2 (1)
Neuroblastoma 2 (3) 3 (4) 5 (3)
Immunodeficiency 3 (4) 0 3 (2)
Other 9 (12) 14 (19) 23 (15)
Previous treatment, n (%)
Cyclophosphamide 61 (81) 58 (78) 119 (80)
Busulfan 32 (43) 31 (42) 63 (42)
Carmustine 0 4 (5) 4 (3)
Etoposide 7 (9) 5 (7) 12 (8)
Melphalan 8 (11) 15 (20) 23 (15)
Total body irradiation 33 (44) 35 (47) 68 (46)
Cyclosporine 38 (51) 35 (47) 73 (49)
Methotrexate 44 (59) 38 (51) 82 (55)
Sirolimus 13 (17) 14 (19) 27 (18)
Tacrolimus 30 (40) 24 (32) 54 (36)
Gemtuzumab ozogamicin 9 (12) 11 (15) 20 (13)
Number of transplantations, n (%)
1 68 (91) 59 (80) 127 (85)
2 5 (7) 13 (18) 18 (12)
3+ 2 (3) 2 (3) 4 (3)
Graft type, n (%)
Autologous 8 (11) 12 (16) 20 (13)
Allogeneic 67 (89) 62 (84) 129 (87)
Days since transplantation, median (range)* 19 (6-48) 18 (0-60) 18 (0-60)
*At randomization.
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the trial had significantly lower CR and day1100 sur-
vival rates (Table 4).
Safety
Grade 3 or higher treatment-related AEs were
reported for 2 patients in arm A and 3 patients in arm
B (P 5 .681) (Table 5). No treatment-related deaths
were reported. The incidence of grade 3 or higher
expected AEs was 52% in arm A and 59% in arm B
(Table 4), a statistically insignificant difference
(P 5 .411). The most common grade 3–5 AEs overall
were renal failure, hypotension, hypoxia, and other pul-
monary events (Table 5); whereas all were less frequent
in arm A events compared with arm B, with the differ-
ence being statistically significant only for hypoxia.
Defibrotide-related AEs leading to discontinuation oftreatment occurred in only 4% of patients (arm A:
n 5 2 [3%; hypotension and diffuse alveolar hemor-
rhage]; arm B: n5 4 [5%; hypotension, gastrointestinal
bleeding, pulmonary hemorrhage, and abdominal
cramps]).
The proportion of patients with treatment-related
AEs was similar in adult and pediatric patients (8% in
both). Analysis of specific event categories by patient
age and treatment arm revealed that in pediatric
patients, the incidence of bleeding events (68% vs
52%; P 5 .377) and hypotension (52% vs 26%; P 5
.083) was higher in arm B compared with arm A.
The percentages of patients with all attributable AEs
(likely or definitely related to defibrotide; 68% vs
39%; P 5 .081) and expected AEs (100% vs 74%;
P 5 .008) were also higher in pediatric patients in
arm B compared with those in arm A. Younger age
Table 2. Characteristics of VOD at Baseline (Treated Population) among All Patients and by Treatment Arm
Characteristic Arm A (n 5 75) Arm B (n 5 74) All Patients (n 5 149)
Days since total bilirubin $2 mg/dL, median (range)* 6 (210 to 40) 4.5 (1-30) 5 (210 to 40)
Total bilirubin, mg/dL, median (range) 6.4 (0.5-52.5) 6.3 (0.9-30.1) 6.4 (0.5-52.5)
Days since VOD diagnosis, median (range)* 2 (1-30) 2 (1-26) 2 (1-30)
Signs and symptoms, n (%)
Jaundice 70 (93) 73 (99) 143 (96)
Ascites 54 (72) 55 (74) 109 (73)
>5% weight gain 60 (80) 55 (74) 115 (77)
RUQ pain 53 (71) 47 (64) 100 (67)
Hepatomegaly 56 (75) 49 (66) 105 (70)
Underwent liver biopsy, n (%) 16 (21) 10 (14) 26 (17)
WHVPG on liver biopsy, mm Hg, median (range) 23 (10-43) 18.5 (11-27) 23 (10-43)
SGOT/AST at hospital admission, U/L, median (range) 28 (8–233) 24 (9–836) 26 (8-836)
ASTelevation at hospital admission, n (%) 17 (23) 14 (19) 31 (21)
SGPT/ALT at hospital admission, U/L, median (range) 26 (6-432) 28 (5-383) 27 (5-432)
Creatinine, mg/dL, median (range) 1.7 (0.2-5.0) 1.5 (0.2-5.5) 1.6 (0.2-5.5)
Abnormal creatinine, n (%) 53 (71) 48 (65) 101 (68)
Abnormal portal flow, n (%) 38 (51) 29 (39) 67 (45)
Requiring oxygen, n (%) 41 (55) 51 (69) 92 (62)
Ventilator-dependent, n (%) 6 (8) 4 (5) 10 (7)
Receiving dialysis, n (%) 3 (4) 4 (5) 7 (5)
Encephalopathy, n (%) 18 (24) 11 (15) 29 (19)
Organ systems compromised, n (%)
1 1 (1) 2 (3) 3 (2)
2 37 (49) 39 (53) 76 (51)
3 34 (45) 30 (41) 64 (43)
4 3 (4) 3 (4) 6 (4)
AST indicates aspartate aminotransferase; RUQ, right upper quadrant; SGOT/AST, aspartate aminotransferase; SGPT/ALT, alanine aminotransferase;
WHVPG, wedged transhepatic venous pressure gradient.
*At randomization. Negative values represent patients who did not have total bilirubin $2 mg/dL until after randomization (VOD diagnosed by liver
biopsy rather than based on clinical criteria).
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bleeding events (P 5 .015) and grade 3–5 expected
AEs (P 5 .004).
Pathology and Radiology
Fifty-two patients (47 of whom were evaluable
for response) had liver specimens evaluable for pathol-
ogy assessment. It should be noted that many of
the specimens came from autopsies (22/52; 42%) or
from patients who underwent biopsies because theirTable 3. Summary of Response and Day +100 Post-HSCT Survival
Characteristic Arm A




Previous sirolimus/tacrolimus 12/28 (43)
No previous sirolimus/tacrolimus 23/44 (52)
Previous gemtuzumab ozogamicin 5/8 (63)
No previous gemtuzumab ozogamicin 30/64 (47)




Previous sirolimus/tacrolimus 9/31 (29)
No previous sirolimus/tacrolimus 24/44 (55)
Previous gemtuzumab ozogamicin 5/9 (56)
No previous gemtuzumab ozogamicin 28/66 (42)
HSCT indicates hematopoietic stem cell transplantation; CR, complete respo
*Of the 35 patients in arm A who achieved CR, 1 did so by day 7, 6 by day 14, 5
numbers were 2, 5, 0, 13, and 10 patients.conditions were not improving. The majority of
patients sampled were confirmed to have VOD alone
(63%) or VOD with another histological diagnosis
(10%) (Table 6). Three other patients with small his-
tological samples had features suggestive of VOD.
One patient with marked hepatic GVHD had rare
focal venular changes considered pathophysiologically
insignificant. None of the 4 patients with the alterna-
tive diagnosis of GVHD without any other confound-
ing features achieved CR, and none was alive at dayamong All Patients and by Treatment Arm
Arm B Total P (A vs B)
30/69 (43) 65/141 (46) .613
19/45 (42) 38/94 (40) .734
11/24 (46) 27/47 (57) .100
9/22 (41) 21/50 (42) .890
21/47 (45) 44/91 (48) .469
6/11 (55) 11/19 (58) .729
24/58 (41) 54/122 (44) .542
29/74 (39) 62/149 (42) .619
20/49 (41) 37/101 (37) .397
9/25 (36) 25/48 (52) .020
9/24 (38) 18/55 (33) .507
20/50 (40) 44/94 (47) .158
5/11 (46) 10/20 (50) .653
24/63 (38) 52/129 (40) .616
nse.
by day 21, 9 by day 28, and 14 after day 29. In arm B, the corresponding
Figure 2. Survival of patients with severe hepatic VOD by treatment
arm post-HSCT (A) and after randomization (B) (treated population).
Kaplan-Meier curves show survival distributions for patients in treat-
ment arms A and B.
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10 of 31 (32%) achieved CR, and 9 of 33 (27%) were
alive at day 1100. These percentages are lower than
those for the overall population, possibly because sam-
pling was biased toward patients with poorer clinical
status and survival.
The distribution of baseline radiologic features
was well balanced between the 2 treatment arms. At
baseline, 99 of the 130 patients evaluated (76%) had as-
cites (75% in arm A and 78% in arm B), including 30
(23%) graded as trace/small (22% in arm A and 24%
in arm B) and 69 (53%) graded as moderate/large
(52% in arm A and 54% in arm B). By day 14, 70 of
97 patients (72%) had ascites, with 23 (24%) graded
as trace/small and 47 (49%) graded as moderate/large.
Absence of ascites at day 14 was seen in 18 of 51 pa-
tients (35%) who achieved CR and in 17 of 47 patients
(36%) who were alive at day 1100. Multivariate step-
wise selection analysis revealed an association between
the absence of ascites at day 14 and better response
(P5 .070). Hepatic venous flow was abnormal (defined
as a loss of the normal triphasic pulsatility pattern) in
36 of 105 patients (34%) at baseline (37% in arm A
and 32% in arm B). At day 14 of treatment, 17 of 81
patients (21%) had abnormal flow, including 13 of46 (28%) who achieved CR and 14 of 43 (33%) who
were alive at day 1100. Abnormal hepatic venous
flow at baseline was not associated with better response
or survival, but abnormal hepatic venous flow at day 14
emerged as a predictor of better outcome by multivar-
iate stepwise selection analysis, associated with both
better response (P 5 .047) and day 1100 survival
(P 5 .007). At baseline, portal venous flow was abnor-
mal in 92 of 129 patients (71%). At day 14, 51 of 98
patients (52%) had abnormal portal flow, including
24 of 53 (45%) who achieved CR and 21 of 49 (43%)
who were alive at day 1100.
Changes in PAI-1 and Total Bilirubin Levels
Changes in PAI-1 and total bilirubin levels with
defibrotide treatment were noted (Figure 4A and B).
There were no significant differences in mean PAI-1
level by treatment arm, between patients with or with-
out CR, or between patients alive or dead at day1100
(Figure 4A); however, mean levels at days 7 and 14
were lower (although not statistically significantly so)
compared with baseline in patients with CR and
patients alive at day 1100, with a similar pattern
observed in both treatment arms.
Pharmacokinetics
Samples for PK analysis were obtained from 11 pa-
tients (8 adult and 3 pediatric patients; 6 patients in
arm A and 5 in arm B). Throughout the PK sampling
period (days 1, 2, and 7), defibrotide concentration in
plasma samples remained constant at approximately
200 mg/mL, consistent with values obtained for thera-
peutic dosing in animal studies. No marked difference
in defibrotide concentration was seen between treat-
ment arms or between dialysis (n 5 4) and nondialysis
patients (n 5 7).DISCUSSION
In this prospective randomized phase II trial, the
largest of its kind to date in patients with severe
VOD after HSCT, defibrotide was administered for
up to 82 days at 25 mg/kg/day and for up to 65 days
at 40 mg/kg/day, and was well tolerated overall. There
were no deaths (including hemorrhage) considered
related to defibrotide. The most common reason for
discontinuing defibrotide treatment was resolution of
VOD (32% of patients overall); only 4% of patients
discontinued treatment because of defibrotide-
related toxicity. The 25-mg/kg/day dosing regimen
had a more favorable safety profile than the 40-mg/
kg/day regimen, most notably in pediatric patients,
with a lower incidence of AEs.
Defibrotide was effective; overall, 46% of the
evaluable patients achieved CR, and 42% of the treated
patients were alive at day 1100 post-HSCT. There
Figure 3. Survival of patients with severe hepatic VODby treatment arm for adult patients post-HSCT (A) and after randomization (B) and for pediatric
patients post-HSCT (C) and after randomization (D) (treated population). Kaplan-Meier curves show survival distributions for patients aged$18 years
and aged\18 years.
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ment arms in CR or day1100 survival rates, or in sur-
vival distributions after HSCT or after randomization.
Given the very high mortality typically associated with
severe VOD [5,6], as well as the presence of MOF in all
but 3 patients at initiation of treatment, these results
are very promising and are consistent with previous
findings from smaller clinical trials of defibrotide in
the treatment of severe VOD/MOF [26-30].
Little has been published on the factors predicting
resolution or response to treatment of severe VOD.
Greater weight gain and higher bilirubin levels have
been associated with the development of severe VOD
and poorer survival [31], whereas in pediatric patients
with VOD, predictors of mortality include an HSCT
donor other than autologous or matched sibling,
presence of hepatic and cutaneous GVHD, maximal
weight gain .9%, presence of pleural effusion, inten-
sive care, and a higher and/or more rapid increase in
bilirubin level [33]. In this trial, CR and day 1100Table 4. Summary of Response and Day +100 Post-HSCT Survival b
among All Patients and by Treatment Arm
Characteristic Arm A
CR, n/N (%) (evaluable population)
Dialysis dependence at baseline 0/3 (0)
Dialysis dependence on study 7/28 (25)
Ventilator dependence at baseline 1/6 (17)
Ventilator dependence on study 4/26 (15)
Day +100 survival, n/N (%) (treated population)
Dialysis dependence at baseline 1/3 (33)
Dialysis dependence on study 6/30 (20)
Ventilator dependence at baseline 1/6 (17)
Ventilator dependence on study 5/27 (19)
HSCT indicates hematopoietic stem cell transplantation; CR, complete respopost-HSCT survival rates were higher in pediatric
patients than adult patients, particularly in arm A.
An association between younger age and better out-
come also has been reported in a previous study of
defibrotide [28], as well as in studies with other treat-
ments [8,34,35]. Although previous gemtuzumab
ozogamicin therapy is known to be a risk factor for
development of severe VOD [36], less is known about
the subsequent response to treatment. The results of
the present study suggest that defibrotide may provide
an effective treatment option for patients who develop
severe VOD after exposure to this agent. Sirolimus
combined with tacrolimus treatment was associated
with decreased day 1100 survival, however. This
may be in part because these agents were continued
during treatment, a practice that has since changed,
with sirolimus now recognized as an important risk
factor for VOD [37,38]. This increased risk of VOD
may be associated with sirolimus’ potent effects on
inhibiting endothelial cell function, acceleratingy Dialysis or Ventilator Dependence at Baseline and on Study,
Arm B All Patients P vs Overall Population
2/4 (50) 2/7 (29) .352
7/30 (23) 14/58 (24) .001
1/4 (25) 2/10 (20) .098
6/27 (22) 10/53 (19) <.001
2/4 (50) 3/7 (43) .946
8/32 (25) 14/62 (23) .002
1/4 (25) 2/10 (20) .166
7/29 (24) 12/56 (21) .002
nse.
Table 5. Summary of Treatment-Emergent AEs in Patients
with Severe Hepatic VOD after HSCT (Treated Population),










Any AE, n (%) 71 (95) 73 (99) 144 (97) 0.367
Grade 3-4 64 (85) 68 (92) 132 (89) 0.303
Grade 5 12 (16) 14 (19) 26 (17) 0.671
Most common grade
3-5 AEs, n (%)
Renal failure 19 (25) 27 (37) 46 (31) 0.159
Hypotension 20 (27) 23 (31) 43 (29) 0.591
Hypoxia 13 (17) 25 (34) 38 (26) 0.025
Pulmonary–other 16 (21) 17 (23) 33 (22) 0.846
Treatment-related AEs, n (%) 5 (7) 7 (10) 12 (8) 0.563
Grade 3-4 2 (3) 3 (4) 5 (3) 0.681
Grade 5 0 0 0 –
Treatment-related bleeding
events, n (%)
0 1 (1) 1 (1) 0.497
Grade 3-4 0 1 (1) 1 (1) 0.497
Grade 5 0 0 0 –
Expected AEs, n (%) 56 (75) 64 (87) 120 (81) 0.097
Grade 3-4 38 (51) 43 (58) 81 (54) 0.412
Grade 5 1 (1) 1 (1) 2 (1) 1.000
AEs indicate adverse events; VOD, veno-occlusive disease;
HSCT, hematopoietic stem cell transplantation.
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injury, preventing healing of hepatic sinusoids after
endothelial injury, and/or increasing the risk of
thrombotic microangiopathy [37,39]. As might be
expected, patients in our trial with advanced MOF,
as reflected by baseline or acquired ventilator and/or
dialysis dependence, had inferior CR and day 1100
post-HSCT survival rates, strongly suggesting that
earlier intervention may be beneficial.
Of note, based on radiologic examination,
abnormal (ie, blunted) hepatic venous flow at day 14
of defibrotide treatment, but not at baseline, was asso-
ciated with improved outcome in our trial, whereas
abnormal portal flow (ie, increased pulsatility or flow
reversal) was not. This may reflect the dominance of
acute hepatic edema as opposed to fibrosis in cases of
reversible VOD. In contrast, portal flow changes can
have multiple causes and are more remote (upstream)
from the primary site of damage, the hepatic sinusoid,
and thus may imply the presence of more extensiveTable 6. Summary of Central Pathology Review Findings
Pathology Finding
All Patients with Pathology A
Day +100 Post-HSCT
VOD, n (%) 33 (6
VOD plus another histologic diagnosis, n (%) 5 (1
Findings consistent with, but not diagnostic
of, VOD, n (%)
3 (6
Alternative diagnosis, n (%)† 10 (1
GVHD, n (%) 4 (8
Insignificant for diagnosis, n (%) 1 (2
HSCT indicates hematopoietic stem cell transplantation; VOD, veno-occlusive
*One patient had no VOD on liver biopsy and was excluded before initiation o
initiation of defibrotide; this patient was removed from the trial.
†In addition to the 4 patients with possible, probable, or definite GVHD, alte
abscesses, and GVHD or cholangitis lenta each in 1 patient.(or irreversible) sinusoidal dysfunction. Future analy-
ses of radiologic findings, including assessment of
hepatic artery resistive indices and correlation of
radiologic features over time with clinical response,
are planned.
Possible early predictive biomarkers for VOD
development have been identified, including elevated
serum PAI-1, elevated N-terminal propeptide of type
III procollagen, elevated t-PA, and low protein C level
[40,41]. In our trial, PAI-1 levels at days 7 and 14 were
decreased baseline levels prior to the start of treatment
in patients who subsequently responded and were alive
at day 1100 post-HSCT. In addition, early stabiliza-
tion of or decreased bilirubin concentration was
associated with better overall outcome. This finding
appears to be consistent with predictive biomarkers
for VOD development and prognosis, as well as with
known effects of defibrotide. These findings suggest
that early changes in both bilirubin and PAI-1 may
help predict response, and also might be useful in early
identification of individuals in whom additional, alter-
native, or experimental therapies should be considered
during defibrotide treatment. Additional exploratory
studies of predictive biomarkers in this trial have
been carried out, and future studies to incorporate
assessment of angiogenic cytokines, including vascular
endothelial growth factor and fibroblast growth factor,
along with analyses of additional endothelial stress
markers, are planned [24].
Given the paucity of viable treatment options for
VOD, as well as the limited nature of supportive care
in this syndrome, defibrotide represents the most
promising therapy for VOD to date, with a recent large
European compassionate-use program also reporting
positive results [42]. In addition to defibrotide’s poten-
tial for treating established VOD as a single agent,
future research directions include the use of defibro-
tide in combination with other agents demonstrating
possible efficacy, such as human protein C con-
centrate, N-acetylcysteine, and methylprednisolone
[34,43,44]. Importantly, initial studies of defibrotide
in VOD prophylaxis have suggested efficacy, withssessment (Evaluable for
Survival) (n 5 52)*
Patients with Pathology Assessment Who







disease; GVHD, graft-versus-host disease.
f defibrotide. One patient had no VOD on liver biopsy performed after
rnative diagnoses were cirrhosis in 2 patients and viral hepatitis, shock,
Figure 4. Mean (standard deviation) PAI-1 (A) and total bilirubin (B) by
treatment arm and outcome in patients with severe hepatic VOD
treated with i.v. defibrotide. Bar charts illustrate PAI-1 levels (A) and
total bilirubin levels (B) by CR/nonresponse, day 1100 post-HSCT sur-
vival/nonsurvival, and treatment arm. D, day; NR, nonresponder.
Biol Blood Marrow Transplant 16:1005-1017, 2010 1015Defibrotide for Severe Veno-Occlusive Diseasesignificant reductions in the incidence of VOD
[45-48]; a prospective randomized, phase II/III trial
has explored prophylactic defibrotide in children
undergoing HSCT with encouraging preliminary
results [49,50].
In conclusion, the results of this dose-finding trial
demonstrate that defibrotide at a dose of either 25 or
40 mg/kg/day appears to be effective in treating severe
VOD after HSCT, with low treatment-related toxic-
ity. As specified a priori, the 25-mg/kg/day dose has
been selected for use in Phase III trials of defibrotide
in VOD, based on its more favorable safety profile. A
large Phase III trial of defibrotide at this dose using
a historical-control methodology has recently been
completed in patients with severe VOD and MOF,
with final results anticipated soon [51,52].ACKNOWLEDGMENTS
We thank Colleen Didas, Caroline Harvey, the
nurses, clinical research coordinators, research
pharmacists, and especially the patients and familiesinvolved in the trial for their participation. We also
thank Krishna Menon, PhD, for his assistance with
pharmacokinetic studies, Nader Rifai, PhD (Chil-
dren’s Hospital of Boston) for his contribution on
biomarkers, and Nicole Carreau, Steve Hill, and
Claire Chapman for their editorial assistance with
the manuscript. Funding for this assistance was
provided in part by Gentium SpA. This study was
supported in part by research funding from Gentium
SpA, by Orphan Drug Products Grant FD-
R-001667, and by the the Richard Corman Multiple
Myeloma Research Fund.
Authorship statement: Paul G. Richardson de-
signed the study performed research and collected
data, analyzed data, and wrote and approved the man-
uscript. Robert J. Soiffer performed research and col-
lected data, and wrote and approved the manuscript.
Joseph H. Antin performed research and collected
data, and wrote and approved the manuscript. Hajime
Uno analyzed data and wrote and approved the manu-
script. Zhezhen Jin analyzed data and wrote and ap-
proved the manuscript. Joanne Kurtzberg performed
research and collected data, and wrote and approved
the manuscript. Paul L. Martin performed research
and collected data, and wrote and approved the manu-
script. Gideon Steinbach performed research and col-
lected data, and wrote and approved the manuscript.
Karen F. Murray performed research and collected
data, and wrote and approved the manuscript. Georgia
B. Vogelsang performed research and collected data,
and wrote and approved the manuscript. Allen R.
Chen performed research and collected data, and
wrote and approved the manuscript. Amrita Krishnan
performed research and collected data, and wrote and
approved the manuscript. Nancy A. Kernan performed
research and collected data, and wrote and approved
the manuscript. David E. Avigan performed research
and collected data, and wrote and approved the manu-
script. Thomas R. Spitzer performed research and col-
lected data, and wrote and approved the manuscript.
Howard M. Shulman performed central reviews and
wrote and approved the manuscript. Donald N. Di
Salvo performed central reviews. Carolyn Revta per-
formed research and collected data, analyzed data,
and wrote and approved the manuscript. Diane War-
ren performed research and collected data, analyzed
data, and wrote and approved the manuscript. Parisa
Momtaz performed research and collected data, and
wrote and approved the manuscript. Gary Bradwin
performed research and collected data, and wrote
and approved the manuscript. L.J. Wei designed the
study and analyzed data. Massimo Iacobelli designed
the study, performed research and collected data,
and wrote and approved the manuscript. George B.
McDonald designed the study, performed research
and collected data, and wrote and approved the manu-
script. Eva C. Guinan designed the study, performed
1016 Biol Blood Marrow Transplant 16:1005-1017, 2010P. G. Richardson et al.research and collected data, analyzed data, and wrote
and approved the manuscript.
Financial disclosure: Paul G. Richardson and Eva
C. Guinan have previously served on Gentium SpA
Advisory Boards. Robert J. Soiffer and George B.
McDonald have acted as a consultant within the past
2 years for Gentium SpA. Massimo Iacobelli is
employed by Gentium SpA, which manufactures
defibrotide. The following authors report no conflict
of interest: Joseph H. Antin, Hajime Uno, Zhezhen
Jin, Joanne Kurtzberg, Paul L. Martin, Gideon Stein-
bach, Karen F. Murray, Georgia B. Vogelsang, Allen
R. Chen, Amrita Krishnan, Nancy A. Kernan, David
E. Avigan, Thomas R. Spitzer, Howard M. Shulman,
Donald N. Di Salvo, Carolyn Revta, Diane Warren,
Parisa Momtaz, Gary Bradwin, and L. J. Wei.SUPPLEMENTARY DATA
Supplementary data associated with this article can
be found, in the online version, at doi:10.1016/
j.bbmt.2010.02.009REFERENCES
1. Richardson P, Guinan E. Hepatic veno-occlusive disease follow-
ing hematopoietic stem cell transplantation. Acta Haematol.
2001;106:57-68.
2. McDonald GB, Sharma P, Matthews DE, et al. Veno-occlusive
disease of the liver after bone marrow transplantation: diagnosis,
incidence, and predisposing factors. Hepatology. 1984;4:116-122.
3. Blostein MD, Paltiel OB, Thibault A, et al. A comparison of
clinical criteria for the diagnosis of veno-occlusive disease of
the liver after bone marrow transplantation. Bone Marrow Trans-
plant. 1992;10:439-443.
4. Lee JL, Gooley T, Bensinger W, et al. Veno-occlusive disease of
the liver after busulfan, melphalan, and thiotepa conditioning
therapy: incidence, risk factors, and outcome. Biol Blood Marrow
Transplant. 1999;5:306-315.
5. Carreras E, Bertz H, Arcese W, et al. Incidence and outcome of
hepatic veno-occlusive disease after blood or marrow transplan-
tation: a prospective cohort study of the European Group for
Blood and Marrow Transplantation. European Group for Blood
and Marrow Transplantation Chronic Leukemia Working
Party. Blood. 1998;92:3599-3604.
6. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive dis-
ease of the liver and multiorgan failure after bone marrow trans-
plantation: a cohort study of 355 patients. Ann InternMed. 1993;
118:255-267.
7. McCune JS, Batchelder A, Deeg HJ, et al. Cyclophosphamide
following targeted oral busulfan as conditioning for hematopoi-
etic cell transplantation: pharmacokinetics, liver toxicity, and
mortality. Biol Blood Marrow Transplant. 2007;13:853-862.
8. Reiss U, Cowan M, McMillan A, et al. Hepatic veno-occlusive
disease in blood and bone marrow transplantation in children
and young adults: incidence, risk factors, and outcome in a cohort
of 241 patients. J Pediatr Hematol Oncol. 2002;24:746-750.
9. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to
hepatic sinusoids: sinusoidal obstruction syndrome (veno-
occlusive disease). Semin Liver Dis. 2002;22:27-42.
10. Shulman HM, Fisher LB, Schoch HG, et al. Veno-occlusive
disease of the liver after marrow transplantation: histological
correlates of clinical signs and symptoms. Hepatology. 1994;19:
1171-1181.11. Shulman HM, Gown AM, Nugent DJ. Hepatic veno-occlusive
disease after bone marrow transplantation: immunohistochemi-
cal identification of the material within occluded central venules.
Am J Pathol. 1987;127:549-558.
12. McCune JS, Batchelder A, Guthrie KA, et al. Personalized
dosing of cyclophosphamide in the total body irradiation-
cyclophosphamide conditioning regimen: a phase II trial in
patients with hematologic malignancy. Clin Pharmacol Ther.
2009;85:615-622.
13. Tay J, Tinmouth A, Fergusson D, et al. Systematic review of
controlled clinical trials on the use of ursodeoxycholic acid for
the prevention of hepatic veno-occlusive disease in hematopoi-
etic stem cell transplantation. Biol Blood Marrow Transplant.
2007;13:206-217.
14. Bearman SI, Lee JL, Baron AE, et al. Treatment of hepatic veno-
occlusive disease with recombinant human tissue plasminogen
activator and heparin in 42 marrow transplant patients. Blood.
1997;89:1501-1506.
15. Bearman SI, Shen DD, Hinds MS, et al. A phase I/II study of
prostaglandin E1 for the prevention of hepatic veno-occlusive
disease after bone marrow transplantation. Br J Haematol.
1993;84:724-730.
16. Haussmann U, Fischer J, Eber S, et al. Hepatic veno-occlusive
disease in pediatric stem cell transplantation: impact of preemp-
tive antithrombin III replacement and combined antithrombin
III/defibrotide therapy. Haematologica. 2006;91:795-800.
17. Eissner G, Multhoff G, Gerbitz A, et al. Fludarabine induces
apoptosis, activation, and allogenicity in human endothelial
and epithelial cells: protective effect of defibrotide. Blood.
2002;100:334-340.
18. Bracht F, Schror K. Isolation and identification of aptamers
from defibrotide that act as thrombin antagonists in vitro.
Biochem Biophys Res Commun. 1994;200:933-937.
19. Coccheri S, Biagi G, Legnani C, et al. Acute effects of defibro-
tide, an experimental antithrombotic agent, on fibrinolysis and
blood prostanoids in man. Eur J Clin Pharmacol. 1988;35:
151-156.
20. Berti F, Rossoni G, Biasi G, et al. Defibrotide, by enhancing
prostacyclin generation, prevents endothelin-1–induced con-
traction in human saphenous veins. Prostaglandins. 1990;40:
337-350.
21. Zhou Q, Chu X, Ruan C. Defibrotide stimulates expression of
thrombomodulin in human endothelial cells. Thromb Haemost.
1994;71:507-510.
22. Falanga A, Marchetti M, Vignoli A, et al. Defibrotide (DF) mod-
ulates tissue factor expression by microvascular endothelial cells
[abstract]. Blood. 1999;94:146a.
23. Falanga A, Marchetti M, Vignoli A, et al. Impact of defibrotide
on the fibrinolytic and procoagulant properties of endothelial
cell macro- and micro-vessels [abstract]. Blood. 2000;96:53a.
24. Benimetskaya L, Wu S, Voskresenskiy AM, et al. Angiogenesis
alteration by defibrotide: implications for its mechanism of
action in severe hepatic veno-occlusive disease. Blood. 2008;
112:4343-4352.
25. Mitsiades CS, Rouleau C, Echart C, et al. Preclinical studies in
support of defibrotide for the treatment of multiple myeloma
and other neoplasias. Clin Cancer Res. 2009;15:1210-1221.
26. Richardson PG, Elias AD, Krishnan A, et al. Treatment of
severe veno-occlusive disease with defibrotide: compassionate
use results in response without significant toxicity in a high-
risk population. Blood. 1998;92:737-744.
27. Chopra R, Eaton JD, Grassi A, et al. Defibrotide for the
treatment of hepatic veno-occlusive disease: results of the
European compassionate-use study. Br J Haematol. 2000;111:
1122-1129.
28. Richardson PG, Murakami C, Jin Z, et al. Multi-institutional
use of defibrotide in 88 patients after stem cell transplantation
with severe veno-occlusive disease and multisystem organ
failure: response without significant toxicity in a high-risk
population and factors predictive of outcome. Blood. 2002;100:
4337-4343.
Biol Blood Marrow Transplant 16:1005-1017, 2010 1017Defibrotide for Severe Veno-Occlusive Disease29. Corbacioglu S, Greil J, Peters C, et al. Defibrotide in the treat-
ment of children with veno-occlusive disease (VOD): a retrospec-
tive multicentre study demonstrates therapeutic efficacy upon
early intervention. Bone Marrow Transplant. 2004;33:189-195.
30. Bulley SR, Strahm B, Doyle J, et al. Defibrotide for the treat-
ment of hepatic veno-occlusive disease in children. Pediatr Blood
Cancer. 2007;48:700-704.
31. Bearman SI, Anderson GL, Mori M, et al. Veno-occlusive
disease of the liver: development of a model for predicting fatal
outcome after marrow transplantation. J Clin Oncol. 1993;11:
1729-1736.
32. Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity
Index for grading acute graft-versus-host disease: retrospective
comparison with Glucksberg grade. Br J Haematol. 1997;97:
855-864.
33. Cheuk DK, Wang P, Lee TL, et al. Risk factors and mortality
predictors of hepatic veno-occlusive disease after pediatric he-
matopoietic stem cell transplantation. Bone Marrow Transplant.
2007;40:935-944.
34. Eber SW, Gungor T, Veldman A, et al. Favorable response of
pediatric stem cell recipients to human protein C concentrate
substitution for veno-occlusive disease. Pediatr Transplant.
2007;11:49-57.
35. Schlegel PG, Haber HP, Beck J, et al. Hepatic veno-occlusive
disease in pediatric stem cell recipients: successful treatment
with continuous infusion of prostaglandin E1 and low-dose hep-
arin. Ann Hematol. 1998;76:37-41.
36. Rajvanshi P, Shulman HM, Sievers EL, et al. Hepatic sinusoidal
obstruction after gemtuzumab ozogamicin (Mylotarg) therapy.
Blood. 2002;99:2310-2314.
37. Cutler C, Stevenson K, Kim HT, et al. Sirolimus is associated
with veno-occlusive disease of the liver after myeloablative allo-
geneic stem cell transplantation. Blood. 2008;112:4425-4431.
38. Platzbecker U, von Bonin M, Goekkurt E, et al. Graft-versus-
host disease prophylaxis with everolimus and tacrolimus is asso-
ciated with a high incidence of sinusoidal obstruction syndrome
and microangiopathy: results of the EVTAC trial. Biol Blood
Marrow Transplant. 2009;15:101-108.
39. Cutler C, Henry NL, Magee C, et al. Sirolimus and thrombotic
microangiopathy after allogeneic hematopoietic stem cell trans-
plantation. Biol Blood Marrow Transplant. 2005;11:551-557.
40. Tanikawa S, Mori S, Ohhashi K, et al. Predictive markers for
hepatic veno-occlusive disease after hematopoietic stem cell
transplantation in adults: a prospective single-center study.
Bone Marrow Transplant. 2000;26:881-886.
41. Pihusch M, Wegner H, Goehring P, et al. Diagnosis of hepatic
veno-occlusive disease by plasminogen activator inhibitor-1
plasma antigen levels: a prospective analysis in 350 allogeneic
hematopoietic stem cell recipients. Transplantation. 2005;80:
1376-1382.42. Carreras E, Olavarria E, Neven B, et al. Defibrotide for the
treatment of veno-occlusive disease post SCT: preliminary
results of EU compassionate use program in 332 patients con-
firms promising activity and manageable toxicity [abstract].
Blood. 2007;110:189a.
43. Al Beihany A, Al Omar H, Sahovic E, et al. Successful treatment
of hepatic veno-occlusive disease after myeloablative allogeneic
hematopoietic stem cell transplantation by early administration
of a short course of methylprednisolone. Bone Marrow Trans-
plant. 2008;41:287-291.
44. Ringden O, Remberger M, Lehmann S, et al. N-acetylcysteine
for hepatic veno-occlusive disease after allogeneic stem cell
transplantation. Bone Marrow Transplant. 2000;25:993-996.
45. Corbacioglu S, Honig M, Lahr G, et al. Stem cell transplanta-
tion in children with infantile osteopetrosis is associated with
a high incidence of VOD, which could be prevented with defib-
rotide. Bone Marrow Transplant. 2006;38:547-553.
46. Dignan F, Gujral D, Ethell M, et al. Prophylactic defibrotide in
allogeneic stem cell transplantation: minimal morbidity and zero
mortality from veno-occlusive disease. Bone Marrow Transplant.
2007;40:79-82.
47. Bonini A, Avanzini P, Masini L, et al. Defibrotide low-dose con-
tinuous infusion from day 11 until day 121 after allogeneic
stem cell transplantation as prophylaxis of veno-occlusive dis-
ease (VOD) of the liver: a single-center experience [abstract].
Blood. 2007;110(11):307b.
48. Qureshi A, Marshall L, Lancaster D. Defibrotide in the preven-
tion and treatment of veno-occlusive disease in autologous and
allogeneic stem cell transplantation in children. Pediatr Blood
Cancer. 2008;50:831-832.
49. Corbacioglu S. Update on the phase II/III study of the incidence
and outcome of VOD with the prophylactic use of defibrotide in
pediatric stem cell transplantation (VOD-DF Study) [abstract].
Bone Marrow Transplant. 2008;41(Suppl 1s):S34.
50. Corbacioglu S. The prospective study on the incidence and out-
come of VOD with the prophylactic use of defibrotide in paedi-
atric stem cell transplantation has completed enrolment: update
on the VOD-DF study [abstract]. BoneMarrow Transplant. 2009;
43(Suppl 1s):S34-S35.
51. Richardson P, Kernan N, Tomblyn M, et al. A phase 3 random-
ized, historically controlled clinical trial investigating the
use of defibrotide in the treatment of severe veno-occlusive
disease post-SCT: a novel approach to the validation of a
promising new drug for the treatment of a life-threatening dis-
ease [abstract]. Blood. 2007;110:189a.
52. Richardson P, Tomblyn M, Kernan N, et al. Defibrotide (DF) in
the treatment of severe hepatic veno-occlusive disease (VOD)
with multi-organ failure (MOF) following stem cell transplanta-
tion (SCT): results of a phase 3 study utilizing a historical con-
trol [abstract]. Blood. 2009;114:272a-273a.
